Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Upadacitinib & Ulcerative colitis (UC)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Upadacitinib is approved by both the FDA and EMA for the treatment of moderately to severely active ulcerative colitis (UC) in adults. This makes it one of the targeted oral therapies available for UC management in these regions.
Ernest-Suarez et al. 2023 Therap Adv Gastroenterol 16: 17562848231158235
Friedberg et al. 2023 Clin Gastroenterol Hepatol 21(7): 1913-1923
Irani et al. 2023 Clin Exp Gastroenterol 16: 21-28
Gastroenterol Hepatol (N Y) 2024 20(12 Suppl 10): 10-12

In multiple phase III clinical trials, upadacitinib has de…

References (Sources)

Clinical Evaluation of Upadacitinib in the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (UC): Patient Selection and Reported Outcomes
Irani et al. 2023 Clin Exp Gastroenterol 16: 21-28
Review
Corticosteroid-Free Remission Through 3 Years of Upadacitinib Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Data From the Phase 3 Long-Term Extension Study U-ACTIVATE
Gastroenterol Hepatol (N Y) 2024 20(12 Suppl 10): 10-12
The role of upadacitinib in the treatment of ulcerative colitis
Jordan & Higgins 2023 Immunotherapy 15(10): 713-727
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
Danese et al. 2022 Lancet 399: 2113-2128
Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data
Danese et al. 2023 Inflammatory Bowel Diseases 29(11): 1723-1729
Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn's Disease: Prospective Real-World Experience
Friedberg et al. 2023 Clin Gastroenterol Hepatol 21(7): 1913-1923
Update on the role of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis
Ernest-Suarez et al. 2023 Therap Adv Gastroenterol 16: 17562848231158235
Review

AI Chat

7/1/2026

Chat with our artificial intelligence: